NASH crash hits another Bay Area 'fatty liver' drug hopeful
Several Bay Area companies are developing drugs against nonalcoholic steatohepatitis, a disease linked to obesity and diabetes, with a potential market of $40 billion in drug sales a year.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news